StockNews.com started coverage on shares of iBio (NYSE:IBIO – Get Free Report) in a research report issued on Wednesday. The brokerage set a “sell” rating on the stock.
iBio Stock Performance
Shares of NYSE:IBIO opened at $4.06 on Wednesday. iBio has a twelve month low of $1.02 and a twelve month high of $49.00. The company has a quick ratio of 0.91, a current ratio of 0.91 and a debt-to-equity ratio of 0.04.
iBio (NYSE:IBIO – Get Free Report) last posted its quarterly earnings results on Friday, February 9th. The company reported ($2.42) earnings per share (EPS) for the quarter.
iBio Company Profile
iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.
Featured Stories
- Five stocks we like better than iBio
- Roth IRA Calculator: Calculate Your Potential Returns
- 3 Value Stocks Too Small For Buffett’s Portfolio
- What Are Dividend Achievers? An Introduction
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Disney Stock Catches 3 Upgrades In a Single Week
Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.
